Differential role of PKC-induced c-Jun in HTLV-1 LTR activation by 12-O-tetradecanoylphorbol-13-acetate in different human T-cell lines

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Abou Kandil, Ammar ^a   Chamias, Rachel ^a   Huleihel, Mahmoud ^a   Godbey, W T ^b   Aboud, Mordechai ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b Tulane University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN C JUN; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN P53; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1; ISOENZYME; SMALL INTERFERING RNA;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; LEUKEMIA CELL LINE; LONG TERMINAL REPEAT; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UPREGULATION; VIRUS ACTIVATION; VIRUS CARRIER; VIRUS CELL INTERACTION; CELL LINE; DNA RESPONSIVE ELEMENT; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; T LYMPHOCYTE;

HUMAN T-LYMPHOTROPIC VIRUS 1;

BINDING SITES; CELL LINE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; ISOENZYMES; JURKAT CELLS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-JUN; RESPONSE ELEMENTS; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TERMINAL REPEAT SEQUENCES; TETRADECANOYLPHORBOL ACETATE;

EID: 84856407045     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029934     Document Type: Article

References (97)

1. Yasunaga J, Matsuoka M, (2007) Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms. Cancer Control 14: 133-140.
2. Yoshida M, (2010) Molecular approach to human leukemia: isolation and characterization of the first human retrovirus HTLV-1 and its impact on tumorigenesis in adult T-cell leukemia. Proc Jpn Acad Ser B Phys Biol Sci 86: 117-130.
3. Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, Devaux C, et al. (2002) The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol pp. 12813-12822.
4. Matsuoka M, Green PL, (2009) The HBZ gene, a key player in HTLV-1 pathogenesis. Retrovirology 6: 71.
5. Duc Dodon M, Mesnard JM, Barbeau B, (2010) Adult T-cell leukemia induced by HTLV-1: before and after HBZ. Med Sci (Paris) 26: 391-396.
6. Barbeau B, Mesnard J-M, (2011) Making sense out of antisense transcription in human T-cell lymphotropic viruses (HTLVs). Viruses 3: 456-468.
7. Matsuoka M, Jeang KT, (2011) Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene 30: 1379-1389.
8. Jeang KT, (2010) Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction? Oncotarget 1: 453-456.
9. Ruggero K, Corradin A, Zanovello P, Amadori A, Bronte V, et al. (2010) Role of microRNAs in HTLV-1 infection and transformation. Mol Aspects Med 31: 367-382.
10. Pichler K, Schneider G, Grassmann R, (2008) MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes. Retrovirology 5: 100.
11. Bellon M, Lepelletier Y, Hermine O, Nicot C, (2009) Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood 113: 4914-4917.
12. Azran-Shaish I, Tabakin-Fix Y, Huleihel M, Bakhanashvili M, Aboud M, (2008) HTLV-1 tax-induced NF-kappaB activation is synergistically enhanced by 12-O-tetradecanoylphorbol-13-acetate: mechanism and implications for Tax oncogenicity. J Mol Med 86: 799-814.
13. Azran I, Jeang KT, Aboud M, (2005) High levels of cytoplasmic HTLV-1 Tax mutant proteins retain a Tax-NF-kB-CBP ternary complex in the cytoplasm. Oncogene 24: 4521-4530.
14. Azran I, Schavinsky-Khrapunsky Y, Aboud M, (2004) Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology 1: 20-43.
15. Sun SC, Yamaoka S, (2005) Activation of NF-kappaB by HTLV-I and implications for cell transformation. Oncogene 24: 5952-5964.
16. Zhi H, Yang L, Kuo YL, Ho YK, Shih HM, et al. (2011) NF-?B hyper-activation by HTLV-1 tax induces cellular senescence, but can be alleviated by the viral anti-sense protein HBZ. LoS Pathog 7: e1002025.
17. Avesani F, Romanell MG, Turci M, Di Gennaro G, Sampaio C, et al. (2010) Association of HTLV Tax proteins with TAK1-binding protein 2 and RelA in calreticulin-containing cytoplasmic structures participates in Tax-mediated NF-kB activation. Virology 408: 39-48.
18. Boxus M, Willems L, (2009) Mechanisms of HTLV-1 persistence and transformation. Br J Cancer 101: 1497-1501.
19. Giam CZ, Jeang KT, (2007) HTLV-1 Tax and adult T-cell leukemia. Front Biosci 12: 1496-1507.
20. Chlichlia K, Khazaie K, (2010) HTLV-1 Tax: linking transformation, DNA damage and apoptotic T-cell death. Chem Biol Interact 188: 359-365.
21. Durkin SS, Guo X, Fryrear KA, Mihaylova VT, Gupta SK, et al. (2008) HTLV-1 Tax oncoprotein subverts the cellular DNA damage response via binding to DNA-dependent protein kinase. J Biol Chem 283: 36311-36320.
22. Marriott SJ, Semmes OJ, (2005) Impact of HTLV-1 Tax on cell cycle progression and cellular DNA damage repair response. Oncogene 24: 5986-5995.
23. Schavinsky-Khrapunsky Y, Priel E, Aboud M, (2008) Dose-dependent dual effect of HTLV-1 Tax oncoprotein on p53-dependent nucleotide excision repair in human T-cells. Int J Cancer 122: 305-316.
24. Saggioro D, (2011) Anti-apoptotic effect of Tax: An NF-kB path or a CREB way? Viruses 3: 1001-1014.
25. Saggioro D, Acquasaliente L, Daprai L, Chieco-Bianchi L, (2003) Inhibition of apoptosis by human T-lymphotropic virus type-1 tax protein. Ann N Y Acad Sci 1010: 591-597.
26. Kinjo T, Ham-Terhune J, Peloponese JMJ, Jeang KT, (2010) Induction of reactive oxygen species by human T-cell leukemia virus type 1 tax correlates with DNA damage and expression of cellular senescence marker. J Virol 84: 5431-5437.
27. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, et al. (2002) c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031-1044.
28. Felsher DW, Bishop JM, (1999) Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A 96: 3940-3944.
29. Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, et al. (1999) Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 274: 7936-7940.
30. Gruhne B, Sompallae R, Marescotti D, Kamranvar SA, Gastaldello S, et al. (2009) The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc Natl Acad Sci U S A 106: 2313-2318.
31. Asquith B, Hanon E, Taylor GP, Bangham CR, (2000) Is human T-cell lymphotropic virus type I really silent? Philos Trans Royal Soc Lond B Biol Sci 355: 1013-1019.
32. Kannagi M, (2007) Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia. Int J Hematol 86: 113-117.
33. Bangham CRM, (2003) The immune control and cell-to-cell spread of human T-lymphotropic virus type 1. J Gen Virol 84: 3177-3189.
34. Bangham CR, Osame M, (2005) Cellular immune response to HTLV-1. Oncogene 24: 6035-6046.
35. Li MY, Lim AG, (2011) Modelling the role of Tax expression in HTLV-I persistence in vivo. Null Math Biol Apr 21 [Epub ahead of print].
36. Kannagi M, Harashima N, Kurihara K, Utsunomiya A, Tanosaki R, et al. (2004) Adult T-cell leukemia: future prophylaxis and immunotherapy. Expert Rev Anticancer Ther 4: 369-376.
37. de Souza JG, da Fonseca FG, Martins ML, Martins CP, de Carvalho LD, et al. (2011) Anti-Tax antibody levels in asymptomatic carriers, oligosymptomatic carriers, patients with rheumatologic disease or with HAM/TSP do not correlate with HTLV-1 proviral load. J Clin Virol 50: 13-18.
38. Akimoto M, Kozako T, Sawada T, Matsushita K, Ozaki A, et al. (2007) Anti-HTLV-1 tax antibody and tax-specific cytotoxic T lymphocyte are associated with a reduction in HTLV-1 proviral load in asymptomatic carriers. J Med Virol 79: 977-986.
39. de la Fuente C, Gupta MV, Klase Z, Strouss K, Cahan P, et al. (2006) Involvement of HTLV-I Tax and CREB in aneuploidy: a bioinformatics approach. Retrovirology 3: 43.
40. Ratner L, Harrington W, Feng X, Grant C, Jacobson S, et al. (2009) Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS ONE 4: e4420.
41. Torgeman A, Ben-Aroya Z, Grunspan A, Zelin E, Butovsky E, et al. (2001) Activation of HTLV-I long terminal repeat by stress-inducing agents and protection of HTLV-I infected T-cells from apoptosis by the viral Tax protein. Exptl Cell Res 271: 169-179.
42. Arima N, Arimura K, Tokito Y, Sakaki Y, Matsushita K, et al. (2004) HTLV-I Tax protein inhibits apoptosis induction but not G1 arrest by pyrrolidinedithiocarbamate, an anti-oxidant, in adult T cell leukemia cells. Exp Hematol 32: 195-201.
43. Ishitsuka K, Tamura K, (2008) Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol 80: 185-196.
44. Faris M, (2008) Potential for molecular targeted therapy for adult T-cell leukemia/lymphoma. Int Rev Immunol 27: 71-78.
45. Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, et al. (2009) Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J Clin Oncol 27: 453-459.
46. Afonso PV, Mekaouche M, Mortreux F, Toulza F, Moriceau A, et al. (2010) Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood 116: 3802-3808.
47. Chamias R, Huleihel M, Aboud M, (2010) The mechanism of HTLV-1 LTR activation by TPA varies in different human T-cell lines: Role of specific PKC isoforms. Leuk Res 34: 93-99.
48. Mor-Vaknin N, Torgeman A, Galron D, Lochelt M, Flugel RM, et al. (1997) The long terminal repeats of human immunodeficiency virus type-1 and human T-cell leukemia virus type-I are activated by 12-O-tetradecanoylphorbol-13-acetate through different pathways. Virology 232: 337-344.
49. Torgeman A, Mor-Vaknin N, Zelin E, Ben-Aroya Z, Lochelt M, et al. (2001) Sp1-p53 heterocomplex mediates activation of HTLV-I long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C. Virology 281: 10-20.
50. Kazanietz MG, (2000) Protein kinase C and novel receptors for the phorbol esters and the second messenger diacylglycerol. Medicina (B Aires) 60 (5 Pt 2): 685-688.
51. Frenkel K, (1989) Oxidation of DNA bases by tumor promoter-activated processes. Environ Health Perspect 81: 45-54.
52. Wei H, Frenkel K, (1992) Suppression of tumor promoter-induced oxidative events and DNA damage in vivo by sarcophytol A: a possible mechanism of antipromotion. Cancer Res 52: 2298-2303.
53. Lin CT, Lin WH, Lee KD, Tzeng PY, (2006) DNA mismatch repair as an effector for promoting phorbol ester-induced apoptotic DNA damage and cell killing: implications in tumor promotion. Int J Cancer 119: 1776-1784.
54. Martelli AM, Sang N, Borgatti P, Capitani S, Neri LM, (1999) Multiple biological responses activated by nuclear protein kinase C. J Cell Biochem 74: 499-521.
55. Reyland ME, (2009) Protein kinase C isoforms: Multi-functional regulators of cell life and death. Front Biosci 14: 2386-2399.
56. Koivunen J, Aaltonen V, Peltonen J, (2006) Protein kinase C (PKC) family in cancer progression. Cancer Lett 235: 1-10.
57. Gonelli A, Mischiati C, Guerrini R, Voltan R, Salvadori S, et al. (2009) Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents. Mini Rev Med Chem 9: 498-509.
58. Lu Z, Liu D, Hornia A, Devonish W, Pagano M, et al. (1998) Activation of protein kinase C triggers its ubiquitination and degradation. Mol Cell Biol 18: 839-845.
59. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, et al. (1991) The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266: 15771-15781.
60. Maor SB, Abramovitch S, Erdos MR, Brody LC, Werner H, (2000) BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol Genet Metab 69: 130-136.
61. Livneh E, Shimon T, Bechor E, Doki Y, Schieren I, et al. (1996) Linking protein kinase C to cell cycle: ecotopic expression of PKC in NIH3T3 cells alters the expression of cyclins and Cdk inhibitors and induces adipogenesis. Oncogene 12: 1545-1555.
62. Jeang KT, Chiu R, Santos E, Kim SJ, (1991) Induction of the HTLV-I LTR by Jun occurs through the Tax-responsive 21-bp elements. Virology 181: 218-227.
63. Lemasson I, Polakowski NJ, Laybourn PJ, Nyborg JK, (2002) Transcription factor binding and histone modifications on the integrated proviral promoter in human T-cell leukemia virus-I-infected T-cells. J Biol Chem 277: 49459-49465.
64. Lemasson I, Polakowski NJ, Laybourn PJ, Nyborg JK, (2004) Transcription regulatory complexes bind the human T-cell leukemia virus 5′ and 3′ long terminal repeats to control gene expression. Mol Cell Biol 24: 6117-6126.
65. Angel P, Karin M, (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072: 129-157.
66. Heinrich R, Kraiem Z, (1997) The protein kinase A pathway inhibits c-jun and c-fos protooncogene expression induced by the protein kinase C and tyrosine kinase pathways in cultured human thyroid follicles. J Clin Endocrinol Metab 82: 1839-1844.
67. Yu X, Luo A, Zhou C, Ding F, Wu M, et al. (2006) Differentiation-associated genes regulated by TPA-induced c-Jun expression via a PKC/JNK pathway in KYSE450 cells. Biochem Biophys Res Commun 342: 286-292.
68. Hai T, Liu F, Coukos WJ, Green MR, (1989) Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev 3: 2083-2090.
69. Karina M, Smealb T, (1992) Control of transcription factors by signal transduction pathways: the beginning of the end. Trends Biochem Sci 17: 418-422.
70. Papavassiliou AG, (1994) The CREB/ATF family of transcription factors: modulation by reversible phosphorylation. Anticancer Res 14: 1801-1805.
71. Hai T, eds. (2006) The ATF transcription factors in cellular adaptive responses Beijing, China and New York, USA Higher Education Press and Springer pp. 322-333.
72. Montminy MR, Bilezikjian LM, (1987) Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 328: 175-178.
73. Newbound GC, O'Rourke JP, Collins ND, DeWille J, Lairmore MD, (1999) Comparison of HTLV-I basal transcription and expression of CREB/ATF-1/CREM family members in peripheral blood mononuclear cells and Jurkat T cells. J Acquir Immune Defic Syndr Hum Retrovirol 20: 1-10.
74. Bosselut R, Duvall JF, Gegonne A, Bailly M, Hemar A, et al. (1990) The product of the c-ets-1 proto-oncogene and the related Ets2 protein act as transcriptional activators of the long terminal repeat of human T cell leukemia virus HTLV-1. EMBO J 9: 3137-3144.
75. Clark NM, Smith MJ, Hilfinger JM, Markovitz DM, (1993) Activation of the human T-cell leukemia virus type I enhancer is mediated by binding sites for Elf-1 and the pets factor. J Virol 67: 5522-5528.
76. Gegonne A, Bosselut R, Bailly RA, Ghysdael J, (1993) Synergistic activation of the HTLV1 LTR Ets-responsive region by transcription factors Ets1 and Sp1. EMBO J 12: 1169-1178.
77. Gitlin SD, Bosselut R, Gegonne A, Ghysdael J, Brady JN, (1991) Sequence-specific interaction of the Ets1 protein with the long terminal repeat of the human T-lymphotropic virus type I. J Virol 65: 5513-5523.
78. MacLachlan TK, Takimoto R, El-Deiry WS, (2002) BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol 22: 4280-4292.
79. Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, et al. (1998) BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16: 1713-1721.
80. Raivich G, (2008) c-Jun expression, activation and function in neural cell death, inflammation and repair. J Neurochem 107: 898-906.
81. Bogoyevitch MA, Kobe B, (2006) Use of JNKs: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Molec Biol Reviews 70: 1061-1095.
82. Shrotriya S, Kundu JK, Na HK, Surh YJ, (2010) Diallyl trisulfide inhibits phorbol ester-induced tumor promotion, activation of AP-1, and expression of COX-2 in mouse skin by blocking JNK and Akt signaling. Cancer Res 70: 1932-1940.
83. Lin CW, Shen SC, Chien CC, Yang LY, Shia LT, et al. (2010) 12-O-tetradecanoylphorbol-13-acetate-induced invasion/migration of glioblastoma cells through activating PKCα/ERK/NF-kB-dependent MMP-9 expression. J Cell Physiol 10: 472-481.
84. Lee KH, Yeh MH, Kao ST, Hung CM, Liu CJ, et al. (2010) The inhibitory effect of hesperidin on tumor cell invasiveness occurs via suppression of activator protein 1 and nuclear factor-kappaB in human hepatocellular carcinoma cells. Toxicol Lett 194: 42-49.
85. Park SA, Kim EH, Na HK, Surh YJ, (2007) KG-135 inhibits COX-2 expression by blocking the activation of JNK and AP-1 in phorbol ester-stimulated human breast epithelial cells. Ann NY Acad Sci 1095: 545-553.
86. Halicka HD, Mitlitski V, Heeter J, Balazs EA, Darzynkiewicz Z, (2009) Attenuation of the oxidative burst-induced DNA damage in human leukocytes by hyaluronan. Int J Mol Med 23: 695-699.
87. Schavinsky-Khrapunsky Y, Huleihel M, Aboud M, Torgeman A, (2003) Role of protein kinase C and the Sp1-p53 complex in activation of p21WAF-1 expression by 12-O-tetradecanoylphorbol-13-acetate in human T-cells. Oncogene 22: 5315-5324.
88. Vigorito E, Plaza S, Mir L, Mongay L, Vinas O, et al. (1999) Contributions of p53 and PMA to g-irradiation induced apoptosis in Jurkat cells. Hematol Cell Therapy 41: 153-161.
89. Pise-Masison CA, Choi KS, Radonovich M, Seong-Jin Kim DJ, Brady JN, (1998) Inhibition of p53 Transactivation Function by the Human T-Cell Lymphotropic Virus Type 1 Tax Protein. J Virol 72: 1165-1170.
90. Gualberto A, Hixon ML, Finco TS, Perkins ND, Nabel GJ, et al. (1995) A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. Mol Cell Biol 15: 3450-3459.
91. Gualberto A, Baldwin ASJ, (1995) p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of HIV-1 long terminal repeat. J Biol Chem 270: 19680-19683.
92. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, et al. (1997) Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth & Differentiation 8: 343-352.
93. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, et al. (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. The Journal of Pathology 221: 49-56.
94. Brosh R, Rotter V, (2009) When mutants gain new powers: news from the mutant p53 field. Nature Rev Cancer 9: 701-713.
95. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, et al. (1993) Gain of function mutations in p53. Nat Genet 4: 42-46.
96. Kato S, Han SY, Liu W, Otsuka K, Shibata H, et al. (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100: 8424-8429.
97. Florins A, Gillet N, Asquith B, Boxus M, Burteau C, et al. (2007) Cell dynamics and immune response to BLV infection: a unifying model. Front Biosci 12: 1520-1531.